Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

AstraZeneca on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in ...

Asian spot liquefied natural gas (LNG) prices fell this week amid low demand during the Lunar New Year holiday in Asia, ...

Despite Trump’s fervent claims that Greenland’s 55,000 residents desire to join the US, both Denmark and Greenland’s local ...

Wall Street is pointing slightly lower in early trading but is on track to close the week with solid gains on healthy ...

Denmark has achieved one of the goals of the Green Tripartite Agreement by designating 75,000 hectares of untouched forest. This is part of the broader plan to enhance biodiversity and allow nature to ...

The 27th Conference of the Parties (COP27) to the United Nation’s Framework Convent on Climate Change was held in Egypt from 6 to ... in the report was Novo Nordisk, which has set itself a ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.